VIRMA

Across TCGA pan-cancer cohorts, VIRMA Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated VIRMA data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher VIRMA Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated VIRMA expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

SCLC, KICH, and COAD are the cancer types where VIRMA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.082	0.708	<.001	36	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
COAD	OS	Median	IV	0.045	0.659	<.001	12	view →
PRAD	DFS	Median	All	0.174	0.888	<.001	6	view →
UCEC	DFS	Median	All	0.958	0.827	.019	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
LUSC	DFS	Median	All	1.000	0.652	.021	5	view →
READ	DFS	Median	IV	0.255	0.628	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

VIRMA–SCLC (OS)

Open the SCLC breakdown →